Literature DB >> 27103403

Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.

Martin G Dalin1, Alexis Desrichard1, Nora Katabi2, Vladimir Makarov1, Logan A Walsh1, Ken-Wing Lee1, Qingguo Wang1, Joshua Armenia1, Lyndsay West3, Snjezana Dogan2, Lu Wang2, Deepa Ramaswami1, Alan L Ho4, Ian Ganly5, David B Solit6, Michael F Berger7, Nikolaus D Schultz8, Jorge S Reis-Filho9, Timothy A Chan10, Luc G T Morris11.   

Abstract

PURPOSE: Salivary duct carcinoma (SDC) is an aggressive salivary malignancy, which is resistant to chemotherapy and has high mortality rates. We investigated the molecular landscape of SDC, focusing on genetic alterations and gene expression profiles. EXPERIMENTAL
DESIGN: We performed whole-exome sequencing, RNA sequencing, and immunohistochemical analyses in 16 SDC tumors and examined selected alterations via targeted sequencing of 410 genes in a second cohort of 15 SDCs.
RESULTS: SDCs harbored a higher mutational burden than many other salivary carcinomas (1.7 mutations/Mb). The most frequent genetic alterations were mutations in TP53 (55%), HRAS (23%), PIK3CA (23%), and amplification of ERBB2 (35%). Most (74%) tumors had alterations in either MAPK (BRAF/HRAS/NF1) genes or ERBB2 Potentially targetable alterations based on supportive clinical evidence were present in 61% of tumors. Androgen receptor (AR) was overexpressed in 75%; several potential resistance mechanisms to androgen deprivation therapy (ADT) were identified, including the AR-V7 splice variant (present in 50%, often at low ratios compared with full-length AR) and FOXA1 mutations (10%). Consensus clustering and pathway analyses in transcriptome data revealed striking similarities between SDC and molecular apocrine breast cancer.
CONCLUSIONS: This study illuminates the landscape of genetic alterations and gene expression programs in SDC, identifying numerous molecular targets and potential determinants of response to AR antagonism. This has relevance for emerging clinical studies of ADT and other targeted therapies in SDC. The similarities between SDC and apocrine breast cancer indicate that clinical data in breast cancer may generate useful hypotheses for SDC. Clin Cancer Res; 22(18); 4623-33. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27103403      PMCID: PMC5026550          DOI: 10.1158/1078-0432.CCR-16-0637

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

Authors:  Devika Gajria; Sarat Chandarlapaty
Journal:  Expert Rev Anticancer Ther       Date:  2011-02       Impact factor: 4.512

3.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

4.  PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.

Authors:  Katsutoshi Oda; Jennifer Okada; Luika Timmerman; Pablo Rodriguez-Viciana; David Stokoe; Keiko Shoji; Yuji Taketani; Hiroyuki Kuramoto; Zachary A Knight; Kevan M Shokat; Frank McCormick
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

5.  Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.

Authors:  Silvana Di Palma; Roderick H W Simpson; Caterina Marchiò; Alena Skálová; Marco Ungari; Ann Sandison; Stephen Whitaker; Suzanne Parry; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2012-10       Impact factor: 5.087

6.  Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.

Authors:  Ilan Weinreb; Salvatore Piscuoglio; Luciano G Martelotto; Daryl Waggott; Charlotte K Y Ng; Bayardo Perez-Ordonez; Nicholas J Harding; Javier Alfaro; Kenneth C Chu; Agnes Viale; Nicola Fusco; Arnaud da Cruz Paula; Caterina Marchio; Rita A Sakr; Raymond Lim; Lester D R Thompson; Simion I Chiosea; Raja R Seethala; Alena Skalova; Edward B Stelow; Isabel Fonseca; Adel Assaad; Christine How; Jianxin Wang; Richard de Borja; Michelle Chan-Seng-Yue; Christopher J Howlett; Anthony C Nichols; Y Hannah Wen; Nora Katabi; Nicholas Buchner; Laura Mullen; Thomas Kislinger; Bradly G Wouters; Fei-Fei Liu; Larry Norton; John D McPherson; Brian P Rubin; Blaise A Clarke; Britta Weigelt; Paul C Boutros; Jorge S Reis-Filho
Journal:  Nat Genet       Date:  2014-09-21       Impact factor: 38.330

7.  Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry.

Authors:  A Skálová; I Stárek; T Vanecek; V Kucerová; L Plank; P Szépe; S Di Palma; I Leivo
Journal:  Histopathology       Date:  2003-04       Impact factor: 5.087

8.  Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma.

Authors:  Shigenori Kadowaki; Yasushi Yatabe; Hitoshi Hirakawa; Azusa Komori; Chihiro Kondoh; Yasuhisa Hasegawa; Kei Muro
Journal:  Case Rep Oncol       Date:  2013-09-10

9.  What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Authors:  A Drilon; G Li; S Dogan; M Gounder; R Shen; M Arcila; L Wang; D M Hyman; J Hechtman; G Wei; N R Cam; J Christiansen; D Luo; E C Maneval; T Bauer; M Patel; S V Liu; S H I Ou; A Farago; A Shaw; R F Shoemaker; J Lim; Z Hornby; P Multani; M Ladanyi; M Berger; N Katabi; R Ghossein; A L Ho
Journal:  Ann Oncol       Date:  2016-02-15       Impact factor: 32.976

10.  Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients.

Authors:  Kuninori Otsuka; Yorihisa Imanishi; Yuichiro Tada; Daisuke Kawakita; Satoshi Kano; Kiyoaki Tsukahara; Akira Shimizu; Hiroyuki Ozawa; Kenji Okami; Akihiro Sakai; Yuichiro Sato; Yushi Ueki; Yukiko Sato; Toyoyuki Hanazawa; Hideaki Chazono; Kaoru Ogawa; Toshitaka Nagao
Journal:  Ann Surg Oncol       Date:  2016-01-20       Impact factor: 5.344

View more
  49 in total

1.  Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor.

Authors:  Justin A Bishop; Jeffrey Gagan; Jeffrey F Krane; Vickie Y Jo
Journal:  Head Neck Pathol       Date:  2020-01-27

2.  Salivary Intraductal Carcinoma Arising within Intraparotid Lymph Node: A Report of 4 Cases with Identification of a Novel STRN-ALK Fusion.

Authors:  Lisa M Rooper; Lester D R Thompson; Jeffrey Gagan; Bahram R Oliai; Ilan Weinreb; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2020-07-13

3.  Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.

Authors:  Richard K Yang; Pei Zhao; Changxue Lu; Jun Luo; Rong Hu
Journal:  Hum Pathol       Date:  2018-09-26       Impact factor: 3.466

4.  Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.

Authors:  Yoshitsugu Mitani; Sue-Hwa Lin; Kristen B Pytynia; Renata Ferrarotto; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2019-11-26       Impact factor: 12.531

Review 5.  Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.

Authors:  Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao
Journal:  Cancer Cytopathol       Date:  2020-05-18       Impact factor: 5.284

6.  Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Authors:  Allen S Ho; Angelica Ochoa; Gowtham Jayakumaran; Ahmet Zehir; Cristina Valero Mayor; Justin Tepe; Vladimir Makarov; Martin G Dalin; Jie He; Mark Bailey; Meagan Montesion; Jeffrey S Ross; Vincent A Miller; Lindsay Chan; Ian Ganly; Snjezana Dogan; Nora Katabi; Petros Tsipouras; Patrick Ha; Nishant Agrawal; David B Solit; P Andrew Futreal; Adel K El Naggar; Jorge S Reis-Filho; Britta Weigelt; Alan L Ho; Nikolaus Schultz; Timothy A Chan; Luc Gt Morris
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

7.  Developing androgen receptor targeting for salivary gland cancers.

Authors:  A L Ho
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

8.  The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype.

Authors:  Maximilian Linxweiler; Fengshen Kuo; Nora Katabi; Mark Lee; Zaineb Nadeem; Martin G Dalin; Vladimir Makarov; Diego Chowell; Snjezana Dogan; Ian Ganly; A Ari Hakimi; Richard J Wong; Nadeem Riaz; Alan L Ho; Timothy A Chan; Luc G T Morris
Journal:  Clin Cancer Res       Date:  2020-02-14       Impact factor: 12.531

9.  Distant metastasis of salivary gland cancer: Incidence, management, and outcomes.

Authors:  Ximena Mimica; Marlena McGill; Ashley Hay; Daniella Karassawa Zanoni; Jatin P Shah; Richard J Wong; Alan Ho; Marc A Cohen; Snehal G Patel; Ian Ganly
Journal:  Cancer       Date:  2020-02-25       Impact factor: 6.860

10.  Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.

Authors:  Pierre Saintigny; Yoshitsugu Mitani; Kristen B Pytynia; Renata Ferrarotto; Dianna B Roberts; Randal S Weber; Merrill S Kies; Sankar N Maity; Sue-Hwa Lin; Adel K El-Naggar
Journal:  Cancer       Date:  2018-10-05       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.